Today, the global anti-aging market is a powerhouse worth over $60 billion, growing at a steady 6-8% annually. Consumers are becoming increasingly aware that true skincare starts with prevention at the foundational level. In parallel, the suncare market is valued at $17 billion. The problem is that most market innovations in these segments are still just “window dressing” – merely scratching the surface by creating endless variations of the same chemical ingredients. At Hard2beat, we look for deep-tech technologies that completely redefine the status quo by solving fundamental problems.
That is why, as part of a 5.4 million PLN round, we invested 3 million PLN in Melanos Care. This company has developed the world’s only patented technology for the mass production of natural, bioidentical human melanin derived from induced pluripotent stem cells (iPSCs).
The End of the Illusion: Moving Beyond Chemical Filters and Synthetics
To understand the weight of this breakthrough, one must look at how we currently protect our skin. Traditional SPF products create a surface-level barrier on the epidermis that easily washes or rubs off, remaining effective for only about two hours. Worse still, they focus primarily on blocking UVB rays, while UVA rays penetrate much deeper – destroying collagen, damaging cellular DNA, and causing massive oxidative stress. This makes UVA the primary culprit behind photoaging and skin cancer. Furthermore, chemical filters are often toxic to the environment and coral reefs, and frequently cause inflammation in humans.
Previous attempts to use synthetic melanin proved to be a dead end. Substances obtained through chemical processes are insoluble, possess an irregular molecular structure, and often contain impurities. Most importantly, they lack biocompatibility, which disqualifies them from advanced dermatological applications and reduces them to the role of a simple technical pigment.
What Exactly Do We Mean by Biocompatibility?
In practice, this refers to the body’s ability to recognize a substance as its own. Synthetic melanin lacks biological and physiological organization – it is not naturally encased in melanosomes, which are specialized organelles surrounded by a lipid bilayer. Because of this, artificial synthetics cannot penetrate living tissue. If applied to the skin, they sit strictly on the surface in the dead layer of the epidermis (stratum corneum), acting as nothing more than a superficial, short-lived filter.
Full biocompatibility – the core breakthrough of Melanos Care – completely changes the mechanism of action. Because the melanin derived from stem cells is delivered in the exact same form as it occurs in the body (within physiological melanosomes), our skin cells do not treat it as an intruder. Living epidermal keratinocytes actively “swallow” these bioidentical vesicles through a process called phagocytosis and transport them into their own interior.
Thanks to this biocompatible mechanism, the melanin penetrates deep into the living tissue and is internalized, mimicking the body’s natural protection process (a physiological tan) and building an intracellular shield that precisely absorbs and scatters UV rays. Additionally, this absolute harmony with human biology ensures full safety and biodegradability – after about a dozen days, our skin can naturally “digest” and expel the pigment using its own lysosomal enzymes. Synthetic chemicals could never replicate this precise cellular dance.
Hard Science: An Internal Biological Shield
The Melanos Care breakthrough is pure deep-tech. The research team developed a unique protocol for differentiating induced pluripotent stem cells, directing them to produce pure eumelanin.
Analysis via EPR (Electron Paramagnetic Resonance) spectroscopy proved beyond doubt that the resulting pigment is pure eumelanin – showing a strong free radical signal at g=2.0 and an absence of high-spin iron at g=4.3, which rules out degradation or the formation of neuromelanin. Furthermore, Transmission Electron Microscopy (TEM) revealed the presence of all four physiological stages of melanosome maturation in the cultures. This means Melanos Care can grow natural, biological “pigment factories” encased in a lipid bilayer in vitro. The nanomechanical properties of these structures were further confirmed using Atomic Force Microscopy (AFM).
This total biocompatibility ensures that once applied, Melanos Care melanin migrates into living keratinocytes. Hard data from reference ex vivo human skin models (Genoskin) proved that this biomelanin persists within living cells, effectively absorbing the full spectrum of UVA and UVB and neutralizing free radicals for up to 14 days after just one application.
Medical Upside: Expanding Beyond Cosmetics
We believe in Melanos Care because their technology reaches far beyond the anti-aging market. The ability to deliver bioidentical melanin opens entirely new doors in targeted medicine. This pigment has massive therapeutic potential for conditions involving melanin deficiency, such as vitiligo or albinism, where the lack of a natural barrier leaves patients with extreme photosensitivity and a drastic risk of skin cancer. Moreover, the anti-inflammatory and antioxidant properties of this innovation – along with substances derived from the production by-products – offer potential for supporting the treatment of atopic dermatitis (AD) and psoriasis.
An Innovative Tyrosinase Inhibitor via a D2C Model
To build early cash flow and validate the team’s operational agility without waiting years for initial revenue, Melanos Care is launching a depigmentation line using a D2C (Direct-to-Consumer) model. However, this is no generic cosmetic. The research team analyzed over 1,000 cinnamic acid derivatives and, under an exclusive license from the Jagiellonian University, is implementing a specific molecule that modulates tyrosinase (the enzyme responsible for discoloration) without any cytotoxic effects. This stands in stark contrast to toxic hydroquinone or invasive, painful treatments like Cosmelan.
Again, the data supports the concept. In reference studies on active in vitro models (MelanoDerm), this innovative molecule reduced melanin levels by 44%. It outperformed the heavily promoted Melasyl (an innovation from La Roche Posay / L’Oréal), surpassed popular kojic acid, and achieved results comparable to – and in some areas better than – the market gold standard from Beiersdorf (Eucerin), Thiamidol.
Furthermore – and this is a key structural difference – this precise derivative is over ten times more potent on enzymes (it has a lower IC50) than the commonly used, simple cinnamic acid found in irritating professional treatments. The Melanos Care molecule guarantees high efficacy without causing skin irritation or reactivity.
A Team That Knows How to Deliver
The primary architect of this technology is Prof. Marcin Majka, PhD, a world-class expert in stem cells who has been researching this field since 1997, with experience from the University of Pennsylvania and the University of Louisville in the USA. His track record includes over 180 scientific publications cited more than 8,000 times, resulting in a formidable h-index of 47. The Professor knows exactly how to implement advanced therapies into GMP standards, which lends immense credibility to the biomelanin scaling process.
Bridging the gap between the lab and the patient is Piotr Sznelewski, MD, a respected Polish dermatologist and aesthetic medicine expert. With years of clinical practice and experience organizing major international aesthetic medicine congresses, he intimately understands the transfer of innovation to clinics and maintains invaluable relationships with industry Key Opinion Leaders (KOLs).
This scientific core is complemented by deep business expertise. Operational strategy and execution are overseen by Konrad Szczukiewicz, an exited founder with a corporate background in building R&D structures for GSK in the USA. Financial discipline and scaling architecture are managed by Marcin Liwoch, a CFO with 25 years of experience who previously built the industrial giant Aluron from the ground up.
Why We Believe Melanos Care is a "Game Changer"
We invested in Melanos Care because, in the world of venture capital, it is rare to find a company that doesn’t just follow market trends but has the power to create them. What Professor Majka’s team is developing isn’t just a “better” sunscreen or another vegan alternative to an existing ingredient. It is a deep-tech technology that introduces a first-in-class solution, initiating an entirely new category of bioactive protective and regenerative products.
In the history of the beauty and aesthetic medicine industries, such paradigm shifts are rare. A perfect business precedent is Olaplex – a company that, thanks to its patented bond-building technology, ceased to be seen as just a “haircare brand.” It created an entirely new, autonomous product class in the consumer’s mind, leading to a massive $15 billion valuation at its NASDAQ debut. A similar breakthrough occurred with Botulinum Toxin (Botox), which redefined anti-aging prevention and opened the era of neuromodulation therapies.
We believe bioidentical human melanin has the potential to become the same unrivaled standard for the global anti-aging and sun protection markets. We are shifting the frontier from a topical, washable SPF layer to internal, biological photoprotection. Melanos Care possesses the technology to not only build a market giant with multi-billion dollar exit potential but, most importantly, to provide real protection for millions of people against the devastating effects of photoaging and skin cancer.